Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-169.49	-130.93	-122.12	-154.54	-145.54	-117.51
Depreciation & Amortization	2.92	3.65	5.64	6.53	4.65	4.16
Stock-Based Compensation	11.44	14.35	17.57	20.08	25.19	20.39
Other Adjustments	15.58	19.55	16.51	3.99	3.81	0.94
Changes in Accounts Payable	2.95	-0.26	-0.37	0.85	-1.61	1.59
Changes in Accrued Expenses	9.29	3.02	-5.4	0.14	3.27	4.15
Changes in Other Operating Activities	1.29	0.57	0.48	1.26	-3.25	6.95
Operating Cash Flow	-130.91	-92.46	-90.9	-108.09	-107.83	-79.29
Capital Expenditures	-0.62	-0.39	-0.81	-11.82	-15.12	-11.84
Purchases of Investments	-54.43	-101.9	-36.72	-104.36	-407.51	-570.39
Proceeds from Sale of Investments	100.7	60.4	134.4	257.9	501.35	302.06
Investing Cash Flow	45.65	-41.89	96.88	141.72	78.71	-280.17
Long-Term Debt Repaid	-	-	-	-	-0.24	-0.06
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-0.24	-0.06
Issuance of Common Stock	-	120	0.49	0.61	2.64	358.09
Repurchase of Common Stock	-	-	-	-	-	-2.04
Net Common Stock Issued (Repurchased)	-	120	0.49	0.61	2.64	356.05
Other Financing Activities	-	-	-0.42	-	-	-
Financing Cash Flow	0.48	120	0.07	0.61	2.4	355.99
Net Cash Flow	-84.9	-14.35	6.04	34.24	-26.73	-3.47
Beginning Cash & Cash Equivalents	-	76.98	70.93	36.7	63.42	66.9
Ending Cash & Cash Equivalents	-84.9	62.63	76.98	70.93	36.7	63.42
Free Cash Flow	-131.53	-92.85	-91.71	-119.91	-122.95	-91.14
FCF Margin	-	-9285.00%	-2547.50%	-	-1639.39%	-
Free Cash Flow Per Share	-6.28	-4.69	-9.10	-12.08	-12.54	-10.70
Levered Free Cash Flow	-153.67	-124.33	-122.57	-157.58	-157.84	-112.57
Unlevered Free Cash Flow	-159.31	-132.57	-129.39	-160.18	-158.19	-114.08

Updated Aug 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q